+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Anticoagulants Reversal Drugs Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2018 to 2026

  • ID: 4759365
  • Report
  • March 2019
  • Region: Global
  • Acute Market Reports
1 of 3

FEATURED COMPANIES

  • Boehringer Ingelheim GmbH
  • CSL Behring Limited
  • Ferring Pharmaceuticals
  • Fresenius Kabi AG
  • Octapharma AG
  • Pfizer, Inc.
  • MORE
The global anticoagulants reversal drugs market expected to expand at a CAGR of 15.3% from 2018 to 2026.

Market Insights

The global anticoagulant reversal drugs market is poised to grow during the forecast period owing to the approval of blockbuster drugs in recent years and strong pipeline driving the market. The U.S. Food and Drug Administration has designated Andexxa (the most recently approved drug for factor Xa inhibitors) as an orphan drug and tagged under the accelerated approval process. European Medicines Agency is also positive to grant approval for andexanet alfa, with Committee for Medicinal Products for Human Use (CMPH) reviewing the application. Idarucizumab, approved in 2015 for an antidote for dabigatran during atrial fibrillation, is currently under clinical trials for multiple conditions such as hemorrhage and stroke. Thus strong pipeline and governmental initiatives will drive the market for anticoagulant reversal drugs market. Drugs type such as prothrombin complex concentrates, Vitamin K, desmopressin which were earlier preferred for containing emergency situation will demonstrate sluggish growth due to the launch of novel drugs with better efficacy and quicker effect. However, high prices of patented drugs would act as a growth barrier in emerging economies.

In terms of geography, North America held the largest share in the global anticoagulant reversal drugs market owing to increased approvals and increasing research and development by major pharmaceutical companies in the region. Europe also held a significant share in the global market attributable to product approvals. The growing incidence of uncontrollable bleeding episodes and usage of anticoagulants will further drive the market in North America and Europe. The U.S. emerged as the largest country-level market due to efficient reimbursement scenario of for drugs, a high cost of the recently approved drugs and accelerated drug approval initiative by U.S. Food and Drug Administration (FDA) to drive the market. The Asia Pacific is set to grow at the fastest rate during the forecast period, driven by rising patient population for diseases such as atrial fibrillation, strokes, and other cardiopulmonary diseases. Ongoing trials in the region will further stimulate market growth in the region. The key players currently engaged in anticoagulant reversal drugs market include Boehringer Ingelheim GmbH, Fresenius Kabi AG, Bausch Health Companies, Inc., CSL Behring Limited, Octapharma AG, Portola Pharmaceuticals, Inc., Perosphere Pharmaceuticals, Inc., and Ferring Pharmaceuticals.

Key Market Movements:
  • Strong pipeline for anticoagulant reversal drugs in North America and Europe to drive the market during the forecast period
  • Growing research and development by pharmaceutical players further boost market growth
  • A rising incidence of uncontrollable bleeding episodes and emergency situation due to the use of anticoagulants
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Boehringer Ingelheim GmbH
  • CSL Behring Limited
  • Ferring Pharmaceuticals
  • Fresenius Kabi AG
  • Octapharma AG
  • Pfizer, Inc.
  • MORE
Chapter 1. Preface
1.1. Report Description
1.1.1. Study Purpose
1.1.2. Target Audience
1.1.3. USP and Key Offerings
1.2. Research Scope
1.3. Research Methodology
1.3.1. Phase I – Secondary Research
1.3.2. Phase II – Primary Research
1.3.3. Phase III – Expert Panel Review
1.3.4. Assumptions
1.4. Market Segmentation

Chapter 2. Executive Summary
2.1. Global Anticoagulant Reversal Drugs Market Portraiture
2.2. Global Anticoagulant Reversal Drugs Market, by Drug Class, 2017 (US$ Mn)
2.3. Global Anticoagulant Reversal Drugs Market, by Geography, 2017 (US$ Mn)

Chapter 3. Anticoagulant Reversal Drugs: Market Dynamics and Outlook
3.1. Market Overview
3.2. Drivers
3.3. Challenges
3.4. Opportunities
3.5. Attractive Investment Proposition, by Geography, 2017
3.6. Competitive Analysis: Global Anticoagulant Reversal Drugs Market, by Key Players, 2017

Chapter 4. Global Anticoagulant Reversal Drugs Market, by Drug Class, 2016-2026 (US$ Mn)
4.1. Overview
4.2. Prothrombin Complex Concentrates (PCC)
4.3. Vitamin K
4.4. Protamine
4.5. Tranexmic Acid
4.6. Desmopressin
4.7. Idarucizumab
4.8. Andexxa
4.9. Pipeline Analysis
4.9.1. Phase III Drugs
4.9.1.1. Octaplex
4.9.2. Phase I and II Drugs (Tabular Representation)

Chapter 5. Global Anticoagulant Reversal Drugs Market, by Geography, 2016 – 2026 (US$ Mn)
5.1. North America Anticoagulant Reversal Drugs Market Analysis, 2016 – 2026
5.1.1. North America Anticoagulant Reversal Drugs Market, by Drug Class, 2016 - 2026 (US$ Mn)
5.1.2. North America Anticoagulant Reversal Drugs Market, by Country, 2016 – 2026 (US$ Mn)
5.1.2.1. U.S.
5.1.2.2. Canada
5.2. Europe Anticoagulant Reversal Drugs Market Analysis, 2016 – 2026
5.2.1. Europe Anticoagulant Reversal Drugs Market, by Drug Class, 2016 - 2026 (US$ Mn)
5.2.2. Europe Anticoagulant Reversal Drugs Market, by Country/Region, 2016 – 2026 (US$ Mn)
5.2.2.1. U.K.
5.2.2.2. Germany
5.2.2.3. Rest of Europe
5.3. Asia Pacific Anticoagulant Reversal Drugs Market Analysis, 2016 – 2026
5.3.1. Asia Pacific Anticoagulant Reversal Drugs Market, by Drug Class, 2016 - 2026 (US$ Mn)
5.3.2. Asia Pacific Anticoagulant Reversal Drugs Market, by Country/Region, 2016 – 2026 (US$ Mn)
5.3.2.1. China
5.3.2.2. Japan
5.3.2.3. Rest of Asia Pacific
5.4. Latin America Anticoagulant Reversal Drugs Market Analysis, 2016 – 2026
5.4.1. Latin America Anticoagulant Reversal Drugs Market, by Drug Class, 2016 - 2026 (US$ Mn)
5.4.2. Latin America Anticoagulant Reversal Drugs Market, by Country/Region, 2016 – 2026 (US$ Mn)
5.4.2.1. Brazil
5.4.2.2. Mexico
5.4.2.3. Rest of Latin America
5.5. Middle East & Africa Anticoagulant Reversal Drugs Market, 2016 – 2026
5.5.1. Middle East & Africa Anticoagulant Reversal Drugs Market, by Drug Class, 2016 - 2026 (US$ Mn)
5.5.2. Middle East & Africa Anticoagulant Reversal Drugs Market, by Region, 2016 – 2026 (US$ Mn)
5.5.2.1. GCC
5.5.2.2. Rest of Middle East & Africa

Chapter 6. Company Profiles
6.1. Boehringer Ingelheim GmbH
6.1.1. Business Description
6.1.2. Financial Information (Subject to Data Availability)
6.1.3. Product Portfolio
6.1.4. News Coverage
6.2. Fresenius Kabi AG
6.3. Pfizer, Inc.
6.4. Bausch Health Companies, Inc.
6.5. Amneal Pharmaceuticals, Inc.
6.6. CSL Behring Limited
6.7. Octapharma AG
6.8. Portola Pharmaceuticals, Inc.
6.9. Perosphere Pharmaceuticals, Inc.
6.10. Ferring Pharmaceuticals

List of Figures
FIG 1. Anticoagulant Reversal Drugs Market: Research Methodology
FIG 2. Anticoagulant Reversal Drugs: Market Segmentation
FIG 3. Global Anticoagulant Reversal Drugs Market, by Drug Class, 2017 (US$ Mn)
FIG 4. Global Anticoagulant Reversal Drugs Market, by Geography, 2017 (US$ Mn)
FIG 5. Attractive Investment Proposition, by Geography, 2017
FIG 6. Competitive Analysis: Global Anticoagulant Reversal Drugs Market, by Key Players, 2017
FIG 7. Global Prothrombin Complex Concentrates (PCC) for Anticoagulant Reversal Drugs Market, 2016-2026 (US$ Mn)
FIG 8. Global Vitamin K for Anticoagulant Reversal Drugs Market, 2016-2026 (US$ Mn)
FIG 9. Global Protamine for Anticoagulant Reversal Drugs Market, 2016-2026 (US$ Mn)
FIG 10. Global Tranexmic Acid for Anticoagulant Reversal Drugs Market, 2016-2026 (US$ Mn)
FIG 11. Global Desmopressin for Anticoagulant Reversal Drugs Market, 2016-2026(US$ Mn)
FIG 12. Global Idarucizumab for Anticoagulant Reversal Drugs Market, 2016-2026(US$ Mn)
FIG 13. Global Andexxa for Anticoagulant Reversal Drugs Market, 2016-2026(US$ Mn)
FIG 14. Global Octaplex for Anticoagulant Reversal Drugs Market, (US$ Mn)
FIG 15. U.S. Anticoagulant Reversal Drugs Market, 2016-2026 (US$ Mn)
FIG 16. Canada Anticoagulant Reversal Drugs Market, 2016-2026 (US$ Mn)
FIG 17. U.K. Anticoagulant Reversal Drugs Market, 2016-2026 (US$ Mn)
FIG 18. Germany Anticoagulant Reversal Drugs Market, 2016-2026 (US$ Mn)
FIG 19. Rest of Europe Anticoagulant Reversal Drugs Market, 2016-2026 (US$ Mn)
FIG 20. China Anticoagulant Reversal Drugs Market, 2016-2026 (US$ Mn)
FIG 21. Japan Anticoagulant Reversal Drugs Market, 2016-2026 (US$ Mn)
FIG 22. Rest of Asia Pacific Anticoagulant Reversal Drugs Market, 2016-2026 (US$ Mn)
FIG 23. Brazil Anticoagulant Reversal Drugs Market, 2016-2026 (US$ Mn)
FIG 24. Mexico Anticoagulant Reversal Drugs Market, 2016-2026 (US$ Mn)
FIG 25. Rest of Latin America Anticoagulant Reversal Drugs Market, 2016-2026 (US$ Mn)
FIG 26. GCC Anticoagulant Reversal Drugs Market, 2016-2026 (US$ Mn)
FIG 27. Rest of Middle East & Africa Anticoagulant Reversal Drugs Market, 2016-2026 (US$ Mn)

List of Tables
TABLE 1 Global Anticoagulant Reversal Drugs Market Portraiture
TABLE 2 Global Anticoagulant Reversal Drugs Market, by Drug Class, 2016 – 2026 (US$ Mn)
TABLE 3 Global Phase I and II Drug for Anticoagulant Reversal Drugs Market
TABLE 4 Global Anticoagulant Reversal Drugs Market, by Geography, 2016 – 2026 (US$ Mn)
TABLE 5 North America Anticoagulant Reversal Drugs Market, by Drug Class, 2016 – 2026 (US$ Mn)
TABLE 6 North America Anticoagulant Reversal Drugs Market, by Country, 2016 – 2026 (US$ Mn)
TABLE 7 Europe Anticoagulant Reversal Drugs Market, by Drug Class, 2016 – 2026 (US$ Mn)
TABLE 8 Europe Anticoagulant Reversal Drugs Market, by Country/Region, 2016 – 2026 (US$ Mn)
TABLE 9 Asia Pacific Anticoagulant Reversal Drugs Market, by Drug Class, 2016 – 2026 (US$ Mn)
TABLE 10 Asia Pacific Anticoagulant Reversal Drugs Market, by Country/Region, 2016 – 2026 (US$ Mn)
TABLE 11 Latin America Anticoagulant Reversal Drugs Market, by Drug Class, 2016 – 2026 (US$ Mn)
TABLE 12 Latin America Anticoagulant Reversal Drugs Market, by Country/Region, 2016 – 2026 (US$ Mn)
TABLE 13 Middle East & Africa Anticoagulant Reversal Drugs Market, by Drug Class, 2016 – 2026 (US$ Mn)
TABLE 14 Middle East & Africa Anticoagulant Reversal Drugs Market, by Region, 2016 – 2026 (US$ Mn)
TABLE 15 Boehringer Ingelheim GmbH: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 16 Fresenius Kabi AG: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 17 Pfizer, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 18 Bausch Health Companies, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 19 Amneal Pharmaceuticals, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 20 CSL Behring Limited: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 21 Octapharma AG: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 22 Portola Pharmaceuticals, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 23 Perosphere Pharmaceuticals, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 24 Ferring Pharmaceuticals: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Boehringer Ingelheim GmbH
  • Fresenius Kabi AG
  • Pfizer, Inc.
  • Bausch Health Companies, Inc.
  • Amneal Pharmaceuticals, Inc.
  • CSL Behring Limited
  • Octapharma AG
  • Portola Pharmaceuticals, Inc.
  • Perosphere Pharmaceuticals, Inc.
  • Ferring Pharmaceuticals
Note: Product cover images may vary from those shown
Adroll
adroll